The year 2020 has seen a lot of development in the way we do business such as new regulations and smarter solutions to solve old and new challenges. PwC has identified the following hot topics for Pharma & Life Sciences which need our special attention:Continue reading PwC’s Pharma & Life Sciences Hot Topics 2020
1. The background in a nutshell
- Until 25th May 2020 all Medtech products that are admitted in Switzerland for the sale can be distributed also in the EU.
- However, currently a new treaty is negotiated by Switzerland and the EU Joint Committee in that regard.
- In case the treaty is not going to be concluded between Switzerland and the EU, all Medtech companies based in Switzerland are considered as not being anymore part of the EU. Indeed this treaty hangs by a hair.
Following the latest developments of the Swiss-EU negotiations concerning the Institutional Agreement and the Mutual Recognition Agreement (MRA), Swiss Medtech companies should be preparing for the case in which MRA would no longer apply to the medical devices after 26th May 2020.Continue reading Swiss Medtech companies – action required for the sale of products in the EU as per May 2020 – Is your business ready for the upcoming changes?